Hecla Mining 주식 가격. HL-B - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NYSE
Hecla Mining Company (HL-B) 시세

Hecla Mining Company (HL-B)

54.20

-1.30

( -2.34% )

업데이트: 01:58:15

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

가격

54.20

매수가

-

매도가

-

거래량

201

54.00 일간 변동폭 54.20

0.00 52주 범위 0.00

market_cap

전일 종가

55.50

개장가

54.20

최근 거래 시간

마지막 거래 시간

02:57:00

재정 규모

US$ 10,894

VWAP

54.20

평균 볼륨(3m)

-

발행 주식

618,233,000

배당수익률

-

주가수익률

-41.43

주당순이익(EPS)

-0.14

매출

721.67M

순이익

-84.77M

섹터

Mng, Quarry Nonmtl Minerals

산업

Mng, Quarry Nonmtl Minerals

웹사이트

www.hecla-mining.com

본부

Wilmington, Delaware, USA

설립됨

-

Hecla Mining Company is listed in the Mng, Quarry Nonmtl Minerals sector of the 뉴욕 증권거래소 with ticker HL-B. The last closing price for Hecla Mining was US$55.50. Over the last year, Hecla Mining shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Hecla Mining currently has 618,233,000 shares in issue. The market capitalisation of Hecla Mining is US$34.31 billion. Hecla Mining has a price to earnings ratio (PE ratio) of -41.43.

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

가장 활성
% 상승자
% 패자

기호	가격	볼륨
CTVInnovid Corp	US$ 3.015 (86.11%)	50.79M
SNOWSnowflake Inc	US$ 170.7193 (32.22%)	46.05M
SRFMSurf Air Mobility Inc	US$ 2.7041 (31.91%)	622.38k
ODVOsisko Development Corporation	US$ 1.94 (31.08%)	1.72M
VATEINNOVATE Corp	US$ 4.76 (22.37%)	79.76k
CATOCato Corp	US$ 4.95 (-18.59%)	157.02k
KLCKindercare Learning Companies Inc	US$ 19.58 (-14.12%)	1.28M
CLCOCool Company LTD	US$ 9.39 (-11.75%)	1.84M
CPACopa Holdings SA	US$ 93.95 (-11.21%)	897.15k
DNMRDanimer Scientific Inc	US$ 5.0813 (-11.01%)	70.16k
CTVInnovid Corp	US$ 3.015 (86.11%)	50.79M
PLTRPalantir Technologies Inc	US$ 61.53 (-0.95%)	46.26M
SNOWSnowflake Inc	US$ 170.7193 (32.22%)	46.05M
NIONIO Inc	US$ 4.70 (1.08%)	41.9M
IONQIonQ Inc	US$ 33.01 (14.38%)	34.21M

manibiotech

manibiotech 1 분 전

However the data of current trial submitted for approval is not "in vitro"

payupdeadbeat

payupdeadbeat 1 분 전

It is clear that the "investment of a lifetime* message is not getting out. I hope the longs are not being hornscwaggled.

Craig305

Craig305 2 분 전

This is the highest day volume since June 2022.

Serpico2005

Serpico2005 2 분 전

HUGE revenue pouring in here, we won't be denied, won't be able the hold it down much longer.

delerious1

delerious1 2 분 전

Milling results soon yet some say that this stock is garbage etc have been here as long as me or longer so that would mean plenty of time to see the patterns and make some really good money....but I bet that they haven't....so it is a bit of a conundrum....why wouldn't they when obviously given the

ExtremelyBullishZig

ExtremelyBullishZig 2 분 전

No...all biotechs are up based on gene editing company success it move the index

richme

richme 2 분 전

Need to Curb Your Enthusiasm just because the share price jumped all the way to $0.0166 share price,
-$0.0015 day change. Isn't that great? We will be heading to Mars soon....no less in Elon Musk's rocket ship or to hell in ________ (add your own).

Quintessence

Quintessence 2 분 전

PDYNW - Nice move today! I will consider buying dips.

JRoon71

JRoon71 3 분 전

TC, I get that. I just meant that in looking at what Italy pays for other drugs, what Amarin wants for Vazkepa is substantially more than MOST drugs on the list.

I'm not talking about the cost to patients, but the cost to the government.

If Vazkepa cost $15 to sell to

dennisdave

dennisdave 3 분 전

BTW, the three companies with approved PD1 inhibitors, which is what the U.S. patent office tried to narrow the combo patent to, are:

Merck = Keytruda

Opdivo = Bristol

Libtayo = Regeneron.
Thanks very helpful.

attilathehunt

attilathehunt 3 분 전

1 buy of 20k will work the same as 2 buys of 10k on squeeze day, no?

NO!!!!!

On squeeze day your first buy order will be much much lower than all subsequent ones...

For example, on Squeeze day (approval) if your first early open trade gets executed at 1.0

bgATL

bgATL 3 분 전

Gaetz is out, my opinion has been he was never really going to be in the position, as it was cover to let him resign from the House before the severe reprimands which could have ruined his chances of a future career. Trump also could now argue he tried to put a pot friendly guy in the office and it

I wonder if .0011 is a good entry? Fishing time. 🎣

konshe

konshe 4 분 전

Strong buy at ask 0.0002, paint sell at bid 0.0001. 0.0002 2mm shares will be gone soon.

al44

The world will become safer when the ‘adults in the room’ are… gone

By Jack Hellner

When Biden and his team of incompetents took over, the media cheered that finally the adults were back in the room; well thankfully, the “children” will be back soon and the U.S.

Real McCoy

Real McCoy 4 분 전

I think they think that announced participation in a hot industry segment should entitle them to valuation levels of those hot industry segment leaders. Despite ALWAYS having virtually no revenue.

KRISGO

KRISGO 4 분 전

Hello Dcaf7, based on the full abstract being released on Nov 25th, can the experts evaluate whether same-day dosing is effective and works better?

PennyMillions852

PennyMillions852 4 분 전

BID building here but...you KNOW what will come next......this is the type of chit that needs to stop for us to move up above .0003!

Hitman970

Hitman970 4 분 전

Why hasn't this historic moment made any mainstream press?
x / twitter and company generate PRs mean nothing.
You are repeating yourself over and over. Do you know Vic? You called him "benign" a while back.

CrashOverride

CrashOverride 4 분 전

If it was DCVax the 2016 paper would cite Liau or Prins as they are the leaders in the field of Dendritic-cell-based vaccines.

They had several papers published before 2016.

It doesn't so it isn't DCVax.

biotechinvestor1

biotechinvestor1 4 분 전

From another poster: “Evotec has already said no thanks. Wall Street said no thanks. When Halozyme management says ok forget about it, we go up $10. We are waiting Ms Helen.”

BamaBreeze

BamaBreeze 4 분 전

Can you bring in the update your referencing(please).

redspinelpinktopaz

redspinelpinktopaz 4 분 전

No. It seems all right to me.

glenn1919

glenn1919 5 분 전

TRNR....CISO....MULN.........................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134

WinstonCup

WinstonCup 5 분 전

Sometimes you make no sense.

Vontobel Financial Produ...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관